New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2014
10:01 EDTM, FRX, DHI, INSM, CACI, LLL, WSM, DAN, ANGI, HAL, VAL, TS, STI, ALB, AZN, D, DD, JCP, JNJ, MCD, MPW, PSA, RVBD, AETOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Aetna (AET) upgraded to Outperform from Neutral at Credit Suisse... Albemarle (ALB) upgraded to Buy from Neutral at BofA/Merrill... AstraZeneca (AZN) upgraded to Hold from Underperform at Jefferies... Dominion (D) upgraded to Buy from Neutral at UBS... DuPont (DD) upgraded to Buy from Neutral at BofA/Merrill... J.C. Penney (JCP) upgraded to Overweight from Neutral at Piper Jaffray... Johnson & Johnson (JNJ) upgraded to Buy from Hold at Jefferies... McDonald's (MCD) upgraded to Overweight from Equal Weight at Morgan Stanley... Medical Properties Trust (MPW) upgraded to Buy from Hold at Jefferies... Public Storage (PSA) upgraded to Buy from Hold at Jefferies... Riverbed (RVBD) upgraded to Hold from Sell at Deutsche Bank... SunTrust (STI) upgraded to Neutral from Underperform at BofA/Merrill... Valspar (VAL) upgraded to Outperform from Neutral at RW Baird... Tenaris (TS) upgraded to Outperform from Sector Perform at Howard Weil... Halliburton (HAL) upgraded to Outperform from Sector Perform at Howard Weil... Forest Labs (FRX) upgraded to Buy from Neutral at Buckingham... D.R. Horton (DHI) upgraded to Buy from Neutral at MKM Partners... Insmed (INSM) upgraded at JMP Securities... CACI International (CACI) upgraded to Overweight from Neutral at JPMorgan... L-3 Communications (LLL) upgraded to Neutral from Underweight at JPMorgan... H&R Block (HRB) upgraded to Buy from Neutral at BTIG... Williams-Sonoma (WSM) upgraded to Buy from Hold at Argus... Dana Holding (DAN) upgraded to Buy from Neutral at Goldman... Angie's List (ANGI) upgraded at Raymond James... Macy's (M) upgraded to Outperform from Market Perform at BMO Capital.
News For AET;ALB;AZN;D;DD;JCP;JNJ;MCD;MPW;PSA;RVBD;STI;TS;VAL;HAL;FRX;DHI;INSM;CACI;LLL;WSM;DAN;ANGI;M From The Last 14 Days
Check below for free stories on AET;ALB;AZN;D;DD;JCP;JNJ;MCD;MPW;PSA;RVBD;STI;TS;VAL;HAL;FRX;DHI;INSM;CACI;LLL;WSM;DAN;ANGI;M the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>
July 14, 2014
14:27 EDTJNJEarnings Preview: J&J pharmaceutical sales expected to drive Q2
Johnson & Johnson (JNJ) is scheduled to report second quarter earnings before the market open on Tuesday, July 15, with a conference call scheduled for 8:30 am ET. Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. EXPECTATIONS: Analysts are looking for earnings per share of $1.55 on revenue of $18.94B, according to First Call. The consensus range for EPS is $1.45-$1.61 on revenue of $18.55B-$19.30B. LAST QUARTER: Johnson & Johnson reported first quarter EPS of $1.54 against estimates of $1.48 on revenue of $18.1B against estimates of $18B. The drug maker raised its fiscal year EPS view to $5.80-$5.90 against a consensus estimate of $5.83. J&J noted a 3.2% decrease in worldwide consumer sales in Q1 but saw a 10.8% increase in worldwide pharmaceutical sales. Primary contributors to operational sales growth in Q1 pharmaceutical sales were Stelara, Invega, Sustenna/Xeplion, Prezista, Velcade and sales of new products. Pharmaceutical sales results were negatively impacted by loss of exclusivity for Aciphex, a proton pump inhibitor for gastrointestinal disorders and Concerta for the treatment of attention deficit hyperactivity disorder. STREET RESEARCH: On July 14, RBC Capital raised its Q2 estimates for Johnson & Johnson to reflect the firm's outlook for higher pharmaceutical sales by the company. The firm raised its price target on the shares to $110 from $106 and kept an Outperform rating on the stock. PRICE ACTION: Shares of Johnson & Johnson are up approximately 8.5% since its last earnings report, and are trading near flat in afternoon trading.
13:11 EDTRVBDRiverbed downgraded to Perform at Oppenheimer
Subscribe for More Information
13:06 EDTRVBDRiverbed downgraded to Perform from Outperform at Oppenheimer
Subscribe for More Information
12:24 EDTJNJJohnson & Johnson technical notes before earnings
The company is scheduled to report before market open on July 15th. The shares in the prior three months have risen by more than 8%, anticipating positive news for the current and forthcoming quarters. At the current price of $105.39, the only remaining established resistance on the daily chart is at the life high of $106.74. If the news and guidance is better than expected, a run to $110, or $115 at an extreme, would be possible. If the news fails to meet expectations or guidance is weak, support would be at $102.70, the 50-day moving average. A break below this uptrend support proxy would be a sell signal in many technical trading systems and would break an uptrend in place since early March of this year. On a sliding scale of increasingly weaker news, supports would next be at $99.96, and then at $96.87.
12:21 EDTRVBDOn The Fly: Midday Wrap
Subscribe for More Information
11:16 EDTTSWTO finds U.S. violates trade rules with tariffs on Chinese steel, solar panels
Subscribe for More Information
10:59 EDTRVBDElliot reaffirms $21 Riverbed bid following Q2 warning
Subscribe for More Information
10:54 EDTRVBDRiverbed Q2 miss strengthens Elliot case, says Wells Fargo
Subscribe for More Information
10:02 EDTRVBDElliott Management reaffirms $21 per share cash bid for Riverbed
Subscribe for More Information
10:00 EDTDANOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:16 EDTRVBDOn The Fly: Pre-market Movers
HIGHER: Citigroup (C), up 3.6% after reporting better than expected Q2 results, announcing $7B settlement with DOJ and FDIC... Apple (AAPL), up 0.7% after Barclays upgrades stock to Overweight, Morgan Stanley raises Apple estimates above consensus... Shire (SHPG), up 1.6% after receiving revised proposal from AbbVie (ABBV) of GPB 53.20 per share, which it says it would be willing to recommend to Shire shareholders. AbbVie is down 2.8% after the news... Mylan (MYL), up 4% after acquiring Abbott's (ABT) non-U.S. developed markets specialty and branded generics business in all-stock transaction valued at about $5.3B. Abbott up 1.6% after the news... Progenics (PGNX), up 13% after FDA says RELISTOR can be approved on data submitted in sNDA... Exelixis (EXEL), up 13% after announcing coBRIM Phase 3 trial met primary endpoint... URS (URS) up 8% after acquired by AECOM Technology (ACM) for $56.31 per share. AECOM shares alos up 2% after deal announcement... Whiting Petroleum (WLL), up 4.5% after agreeing to acquire Kodiak Oil & Gas (KOG) in a $6B transaction. Kodiak Oil & Gas up 3%... Kandi Technologies (KNDI), up 11% after announcing JV's sale of 4,114 EVs in Q2. LOWER: Riverbed (RVBD), down 4.5% after saying it sees its Q2 adjusted EPS at low end of 26c-28c range... Harmonic (HLIT), down 13% after reporting preliminary Q2 earnings results.. EBay (EBAY), down 0.5% after downgraded at Pacific Crest, confirming partnership plans with Sotheby's (BID).
09:14 EDTRVBDRiverbed falls on Q2 EPS view, levels to watch
Subscribe for More Information
08:32 EDTRVBDRiverbed CEO says Q2 sales 'below expectations'
Subscribe for More Information
08:31 EDTRVBDRiverbed sees Q2 adjusted EPS at low end of 26c-28c range, consensus 27c
Cuts Q2 adjusted revenue view to $264M-$265M from $274M-$280M, consensus $277.42M. “Second quarter sales were below our expectations, principally in North America as we experienced longer sales cycles on some of our larger and more complex deals. We have carefully reviewed our opportunities and prospects for the remainder of the year and continue to have confidence in our ability to grow the business and deliver targeted earnings performance,” said Jerry M. Kennelly, chairman and CEO, Riverbed. “During the quarter, we continued to prudently manage expenses and focus on achieving operating leverage, as demonstrated by our solid EPS performance within our guided range.”
08:30 EDTJNJJohnson & Johnson should be bought on any weakness, says RBC Capital
Subscribe for More Information
05:46 EDTDANDana Holding downgraded to Neutral from Buy at Goldman
Goldman Sachs downgraded Dana Holding to Neutral citing valuation and risk to guidance given the company's exposure to Latin America. The firm lowered its price target for shares to $27 from $28.
July 13, 2014
15:18 EDTJCPJ.C. Penney CEO successor search faces setback, WSJ says
It appears that J.C. Penney (JCP) is not having an easy time of identifying a successor for current CEO Myron Ullman, says the Wall Street Journal. According to the WSJ report, Mindy Grossman, CEO of HSN (HSNI), who is considered the lead candidate for Ullman's position, had been in talks with J.C. Penney but could not agree on terms and negotiations broke down moths ago. Reference Link
July 11, 2014
15:42 EDTTSU.S. Steel, AK Steel, Tenaris jump after U.S. decision on steel-tube duties
Subscribe for More Information
09:56 EDTHALHalliburton announces joint venture with SPT Energy Group
Subscribe for More Information
07:36 EDTJNJJohnson & Johnson Q2 EPS likely to exceed expectations, says Bernstein
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use